Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Annala, Matti; Vandekerkhove, Gillian; Khalaf, Daniel; Taavitsainen, Sinja; Beja, Kevin; W. Warner, Evan; Sunderland, Katherine; Kollmannsberger, Christian; J. Eigl, Bernhard; L. Finch, Daygen; D. Oja, Conrad; Vergidis, Joanna; Zulfiqar, Muhammad; Azad, Arun; Nykter, Matti; Gleave, Martin; W. Wyatt, Alexander; N., Kim

doi:10.1158/2159-8290.cd-17-0937

Public

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Published in Cancer Discovery • Jan 24, 2018

Authors:

Matti Annala

Gillian Vandekerkhove

Daniel Khalaf

Abstract

Abstract Primary resistance to androgen receptor (AR)–directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with treatment-naïve mCRPC to abiraterone or enzalutamide and performed whole-exome and deep targeted 72-gene sequencin...

Subject

Enzalutamide

Prostate cancer

Abiraterone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!